Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema

Diffuse Diabetic Macular Edema Clinical Trial

Official title:
A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of iCo-007 Intravitreal Injection in Subjects With Diffuse Diabetic Macular Edema

Status Completed

Clinical Trial Summary

The goal of the study is to evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse diabetic macular edema.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00886808
Study type	Interventional
Source	iCo Therapeutics Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	February 2008
Completion date	June 2010

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00571142` - Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema	Phase 3
Withdrawn	`NCT00567372` - POSTERIOR SUB-TENON'S Avastin	Phase 4
Recruiting	`NCT00999791` - Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema	Phase 1
Withdrawn	`NCT00600301` - Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study	Phase 3
Recruiting	`NCT01218750` - Triple Therapy for Diffuse Diabetic Macular Edema	N/A